Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) has been assigned an average recommendation of “Hold” from the twelve brokerages that are presently covering the company, MarketBeat reports. Nine analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $146.17.
A number of equities research analysts have issued reports on DGX shares. Leerink Partnrs restated a “market perform” rating on shares of Quest Diagnostics in a report on Monday, February 26th. StockNews.com raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Friday. Jefferies Financial Group raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and upped their price objective for the company from $140.00 to $155.00 in a research report on Wednesday, February 7th. Citigroup upped their price objective on shares of Quest Diagnostics from $135.00 to $145.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th. Finally, UBS Group upped their price objective on shares of Quest Diagnostics from $139.00 to $146.00 and gave the company a “neutral” rating in a research report on Wednesday, April 24th.
Read Our Latest Stock Analysis on DGX
Insider Activity
Institutional Investors Weigh In On Quest Diagnostics
Several hedge funds have recently bought and sold shares of DGX. NBC Securities Inc. acquired a new stake in shares of Quest Diagnostics during the third quarter worth $25,000. Altshuler Shaham Ltd acquired a new stake in shares of Quest Diagnostics during the fourth quarter worth $26,000. VisionPoint Advisory Group LLC increased its stake in Quest Diagnostics by 100.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in Quest Diagnostics in the 4th quarter valued at $29,000. Finally, Spartan Planning & Wealth Management acquired a new stake in Quest Diagnostics in the 4th quarter valued at $31,000. 88.06% of the stock is currently owned by institutional investors and hedge funds.
Quest Diagnostics Trading Up 0.9 %
NYSE DGX opened at $141.28 on Friday. Quest Diagnostics has a twelve month low of $119.59 and a twelve month high of $145.62. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97. The stock has a market cap of $15.70 billion, a price-to-earnings ratio of 19.01, a PEG ratio of 3.08 and a beta of 0.88. The firm’s 50 day moving average price is $134.34 and its two-hundred day moving average price is $133.03.
Quest Diagnostics (NYSE:DGX – Get Free Report) last issued its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.86 by $0.18. The company had revenue of $2.37 billion during the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The company’s revenue for the quarter was up 1.7% on a year-over-year basis. During the same quarter last year, the business posted $2.04 EPS. Equities analysts anticipate that Quest Diagnostics will post 8.78 EPS for the current year.
Quest Diagnostics Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Stockholders of record on Monday, July 8th will be paid a dividend of $0.75 per share. The ex-dividend date is Monday, July 8th. This represents a $3.00 annualized dividend and a dividend yield of 2.12%. Quest Diagnostics’s dividend payout ratio (DPR) is currently 40.38%.
Quest Diagnostics Company Profile
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.
Recommended Stories
- Five stocks we like better than Quest Diagnostics
- What Investors Need to Know to Beat the Market
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- How Investors Can Find the Best Cheap Dividend Stocks
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.